DUBLIN, Ohio--(BUSINESS WIRE)--Neoprobe Corporation (OTCBB: NEOP), a diversified developer of innovative oncology and cardiovascular surgical and diagnostic products, today announced that concurrent with the authorization by FDA to commence patient enrollment in a Phase 3 multi-center clinical study of Lymphoseek, the Company completed the second closing of $3 million in financing committed to by Platinum-Montaur Life Sciences LLC (Montaur) in December of last year. The closing with Montaur provides Neoprobe with funding to commence its Phase 3 clinical studies of Lymphoseek in patients with breast cancer or melanoma and head and neck squamous cell carcinoma.
